- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT07946666
A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.
This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.
Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Dimitra Diamantopoulou
- E-Mail: dimitra@epetome.com
Studienorte
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89101
- Citruslabs
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults aged 18-65 years.
- Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
- Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
- Currently on a stable GLP-1 dose as directed by their prescribing physician.
- Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
- Willing and able to provide informed consent prior to enrollment.
- In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
- Reside in the United States.
Exclusion Criteria:
- Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
- Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
- Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
- Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
- Anyone currently participating or planning to participate in another research study during the study period.
- Currently receiving immunosuppressant therapy of any kind.
- Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
- Reside in Hawaii.
- Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Synbiotic Dual Cap® Arm
|
Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Overall Gastrointestinal Comfort
Zeitfenster: Baseline to Week 12
|
Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bowel Regularity
Zeitfenster: Baseline to Week 12
|
Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Bloating
Zeitfenster: Baseline to Week 12
|
Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Constipation
Zeitfenster: Baseline to Week 12
|
Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Diarrhea
Zeitfenster: Baseline to Week 12
|
Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Nausea
Zeitfenster: Baseline to Week 12
|
Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires |
Baseline to Week 12
|
|
Change in Post-Meal Fullness Comfort
Zeitfenster: Baseline to Week 12
|
Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires |
Baseline to Week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Participant Perception of Effect on Overall Gastrointestinal Comfort
Zeitfenster: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bowel Regularity
Zeitfenster: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Bloating
Zeitfenster: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Constipation
Zeitfenster: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Diarrhea
Zeitfenster: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Nausea
Zeitfenster: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
|
Participant Perception of Effect on Post-Meal Fullness Comfort
Zeitfenster: Week 4, Week 8, and Week 12
|
Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires |
Week 4, Week 8, and Week 12
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen des endokrinen Systems
- Ernährungsstörungen
- Stoffwechselerkrankungen
- Überernährung
- Körpergewicht
- Anzeichen und Symptome, Verdauungstrakt
- Störungen des Glukosestoffwechsels
- Diabetes Mellitus
- Übergewicht
- Pathologische Zustände, Anzeichen und Symptome
- Ernährungs- und Stoffwechselerkrankungen
- Anzeichen und Symptome
- Fettleibigkeit
- Diabetes mellitus, Typ 2
- Brechreiz
- Verstopfung
- Durchfall
Andere Studien-ID-Nummern
- EPETO-21217
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .